交易中 11-18 10:57:19 美东时间
-0.150
-3.21%
Cormedix (NASDAQ:CRMD) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.10) by 90 percent. This is a 133.33 percent decrease over earnings of $0.57 per share from the
11-12 20:42
CorMedix acquires Heron Therapeutics assets for $222.6 million upfront, adding four commercial hospital therapies to expand its acute care reach.
11-10 01:09
Adds four commercial-stage products — ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL® — to CorMedix's hospital- and acute-care-focused commercial platformUpfront consideration consisting of $145 million in cash, subject
11-09 20:07
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
Companies Reporting Before The Bell • Palladyne AI (NASDAQ:PDYN) is projected t...
03-05 19:11
Cormedix (NASDAQ:CRMD) is gearing up to announce its quarterly earnings on Thur...
03-05 02:02
Cormedix (NASDAQ:CRMD) sees FY2026 sales of $300.000 million-$320.000 million.
01-08 21:41
CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced an addition to its executive
01-08 21:11
CorMedix posts strong Q3 results with $104 million in revenue, higher DefenCath sales, and raises 2025 guidance following Melinta integration progress.
2025-11-13 00:49
CorMedix Inc. announced that its Large Dialysis Organization (LDO) customer has begun ordering and implementing DefenCath, targeting at least 50% more patients than previously planned. As a result, the company has amended its agreement with the LDO and raised its second quarter net sales guidance to $35 million to $40 million from $31 million.
2025-06-23 11:30